Logo image of AGL

AGILON HEALTH INC (AGL) Stock Fundamental Analysis

NYSE:AGL - New York Stock Exchange, Inc. - US00857U1079 - Common Stock - Currency: USD

3.48  +0.09 (+2.65%)

After market: 3.48 0 (0%)

Fundamental Rating

2

AGL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 109 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of AGL have multiple concerns. AGL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AGL had negative earnings in the past year.
AGL had a negative operating cash flow in the past year.
In the past 5 years AGL always reported negative net income.
In the past 5 years AGL always reported negative operating cash flow.
AGL Yearly Net Income VS EBIT VS OCF VS FCFAGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -100M -200M -300M -400M

1.2 Ratios

With a Return On Assets value of -18.40%, AGL is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
AGL has a worse Return On Equity (-66.94%) than 71.30% of its industry peers.
Industry RankSector Rank
ROA -18.4%
ROE -66.94%
ROIC N/A
ROA(3y)-15.66%
ROA(5y)-26.12%
ROE(3y)-29.05%
ROE(5y)-181.24%
ROIC(3y)N/A
ROIC(5y)N/A
AGL Yearly ROA, ROE, ROICAGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

AGL has a Gross Margin of 2.00%. This is amonst the worse of the industry: AGL underperforms 84.26% of its industry peers.
In the last couple of years the Gross Margin of AGL has declined.
The Profit Margin and Operating Margin are not available for AGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.83%
GM growth 5YN/A
AGL Yearly Profit, Operating, Gross MarginsAGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 10 -10 -20 -30

More info and screens

3

2. Health

2.1 Basic Checks

AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGL has less shares outstanding
AGL has a better debt/assets ratio than last year.
AGL Yearly Shares OutstandingAGL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 100M 200M 300M 400M
AGL Yearly Total Debt VS Total AssetsAGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 1.81, we must say that AGL is in the distress zone and has some risk of bankruptcy.
AGL's Altman-Z score of 1.81 is in line compared to the rest of the industry. AGL outperforms 48.15% of its industry peers.
AGL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
AGL has a Debt to Equity ratio of 0.06. This is in the better half of the industry: AGL outperforms 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 1.81
ROIC/WACCN/A
WACC9.24%
AGL Yearly LT Debt VS Equity VS FCFAGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M 600M 800M 1B

2.3 Liquidity

AGL has a Current Ratio of 1.29. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
AGL has a Current ratio of 1.29. This is in the lower half of the industry: AGL underperforms 61.11% of its industry peers.
AGL has a Quick Ratio of 1.29. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
AGL's Quick ratio of 1.29 is in line compared to the rest of the industry. AGL outperforms 46.30% of its industry peers.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.29
AGL Yearly Current Assets VS Current LiabilitesAGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 500M 1B

More info and screens

6

3. Growth

3.1 Past

AGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -254.55%.
Looking at the last year, AGL shows a very strong growth in Revenue. The Revenue has grown by 27.75%.
The Revenue has been growing by 52.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-254.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
Revenue 1Y (TTM)27.75%
Revenue growth 3Y52.45%
Revenue growth 5YN/A
Sales Q2Q%19.35%

3.2 Future

AGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.54% yearly.
Based on estimates for the next years, AGL will show a quite strong growth in Revenue. The Revenue will grow by 19.06% on average per year.
EPS Next Y-21.43%
EPS Next 2Y8.46%
EPS Next 3Y13.87%
EPS Next 5Y22.54%
Revenue Next Year34.87%
Revenue Next 2Y21.16%
Revenue Next 3Y19.08%
Revenue Next 5Y19.06%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AGL Yearly Revenue VS EstimatesAGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
AGL Yearly EPS VS EstimatesAGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGL Price Earnings VS Forward Price EarningsAGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGL Per share dataAGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

AGL's earnings are expected to grow with 13.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.46%
EPS Next 3Y13.87%

More info and screens

0

5. Dividend

5.1 Amount

AGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGILON HEALTH INC

NYSE:AGL (2/4/2025, 8:25:36 PM)

After market: 3.48 0 (0%)

3.48

+0.09 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners87.22%
Inst Owner Change-0.11%
Ins Owners1.78%
Ins Owner Change1.3%
Market Cap1.43B
Analysts55.17
Price Target2.94 (-15.52%)
Short Float %8.29%
Short Ratio5.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-78.49%
Min EPS beat(2)-171.08%
Max EPS beat(2)14.11%
EPS beat(4)2
Avg EPS beat(4)-43.31%
Min EPS beat(4)-171.08%
Max EPS beat(4)18.64%
EPS beat(8)3
Avg EPS beat(8)-31.01%
EPS beat(12)3
Avg EPS beat(12)-48.98%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.08%
Min Revenue beat(2)-5.86%
Max Revenue beat(2)-2.29%
Revenue beat(4)1
Avg Revenue beat(4)-1.6%
Min Revenue beat(4)-5.86%
Max Revenue beat(4)2.73%
Revenue beat(8)5
Avg Revenue beat(8)1.12%
Revenue beat(12)9
Avg Revenue beat(12)1.54%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.08%
PT rev (3m)-55.73%
EPS NQ rev (1m)-0.48%
EPS NQ rev (3m)-33.54%
EPS NY rev (1m)-4.21%
EPS NY rev (3m)-67.03%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)3.52%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.27
P/FCF N/A
P/OCF N/A
P/B 2.49
P/tB 3
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS12.99
BVpS1.4
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.4%
ROE -66.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 2%
FCFM N/A
ROA(3y)-15.66%
ROA(5y)-26.12%
ROE(3y)-29.05%
ROE(5y)-181.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.83%
GM growth 5YN/A
F-Score2
Asset Turnover2.56
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 191.38%
Cap/Sales 0.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.29
Altman-Z 1.81
F-Score2
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)160.53%
Cap/Depr(5y)101.54%
Cap/Sales(3y)0.88%
Cap/Sales(5y)0.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-254.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
EPS Next Y-21.43%
EPS Next 2Y8.46%
EPS Next 3Y13.87%
EPS Next 5Y22.54%
Revenue 1Y (TTM)27.75%
Revenue growth 3Y52.45%
Revenue growth 5YN/A
Sales Q2Q%19.35%
Revenue Next Year34.87%
Revenue Next 2Y21.16%
Revenue Next 3Y19.08%
Revenue Next 5Y19.06%
EBIT growth 1Y-142.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.67%
EBIT Next 3Y24.69%
EBIT Next 5Y23.62%
FCF growth 1Y-13.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.33%
OCF growth 3YN/A
OCF growth 5YN/A